Anew, highly selective intravenous (IV) beta-agonist in development—MN-221 (bedoradrine sulfate)—improves lung function in patients with stable, moderate-to-severe chronic obstructive pulmonary disease (COPD), according to a dose-ranging study presented at the meeting.
In development for the treatment of acute exacerbations of asthma and COPD, MN-221 has higher selectivity for the beta2-receptors than the currently used beta-agonists (ie, albuterol, levalbuterol, terbutaline), which suggests that the cardiac-stimulating action on beta1-receptors may be reduced with this investigational agent. Therefore, MN-221 may reduce bronchospasm, while minimizing cardiovascular complications.
James Pearle, MD, and colleagues at California Research Medical Group in Fullerton, examined 3 dose levels of MN-221 (300 μg, 600 μg, and 1200 μg IV) in 16 patients with stable, moderate- to-severe COPD. The patients were randomized to receive either MN-221 or placebo in a 3:1 ratio—half of the dose was given over 15 minutes, followed by the remaining dose over 45 minutes, for a total 1-hour infusion.
Lung function improved with all 3 doses; the improvement was significant compared with placebo at the 600-μg and 1200-μg doses. The forced expiratory volume in 1 second (FEV1) increases from baseline were 9.2% with the 300-μg dose (not a significant difference), 16.2% with the 600-μg dose (P = .02), and 21.5% with the 1200-μg dose (P = .025). In comparison, FEV1 declined by 4% in patients receiving placebo infusion.
The researchers noted that MN-221 at doses of 600 μg and 1200 μg improved lung function for at least 6 hours compared with placebo